medigraphic.com
ISSN 0326-3428 (Impreso)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2024, Número 4

<< Anterior

Rev Nefrol Dial Traspl 2024; 44 (4)


En la búsqueda de la nefroprotección. Los pilares del tratamiento 2024

Inserra F

Idioma: Ingles.
Referencias bibliográficas: 78
Paginas: 211-222
Archivo PDF: 495.05 Kb.


RESUMEN

La enfermedad renal crónica tiene, luego de casi 20 años de “status quo”, importantes progresos en términos de nefro protección. En los últimos 5 años se han sumado, a la ya consolidada protección renal brindada por las drogas que bloquean el Sistema Renina Angiotensina, otras tres estrategias que han confirmado beneficiosos significativos sobre el riñón y su funcionalidad. Ellas son: los inhibidores tipo 2 del co-trasporte sodioglucosa, los antagonistas del receptor mineralocorticoide, particularmente los no esteroideos, y recientemente los agonistas del receptor GLP-1. Estos dos últimos con evidencias sólidas en la enfermedad renal secundaria a diabetes mellitus tipo 2 por ahora. Esta revisión describe los principales resultados que avalan sus efectos e indicaciones de estas drogas. Los mismos dan soporte al creciente consenso en su uso combinado a maneras de pilares del tratamiento nefroprotector. Es posible que con nuevos resultados y entendimiento de como asociar, de manera preferente, estas estrategias en cada paciente o fenotipo clínico podamos obtener beneficios crecientes para cambiar significativamente el rumbo de la ERC.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ferder LF, Inserra F, Daccordi H, Smith RD. Enalaprilimproved renal function and proteinuria in chronicglomerulopathies. Nephron. 1990;55 Suppl 1:90-95.

  2. Ferder L, Daccordi H, Martello M, Panzalis M, InserraF. Angiotensin converting enzyme inhibitors versuscalcium antagonists in the treatment of diabetichypertensive patients. Hypertension. 1992;19(2 Suppl):II237-242.

  3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. Theeffect of angiotensin-converting-enzyme inhibitionon diabetic nephropathy. The Collaborative StudyGroup. N Engl J Med. 1993;329(20):1456-1462.

  4. Maschio G, Alberti D, Janin G, Locatelli F, MannJF, Motolese M, et al. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal InsufficiencyStudy Group. Effect of the angiotensin-convertingenzymeinhibitor benazepril on the progressionof chronic renal insufficiency. N Engl J Med.1996;(334):939-945

  5. The GISEN Group (Gruppo Italiano di StudiEpidemiologici in Nefrologia). Randomised placebocontrolledtrial of effect of ramipril on decline inglomerular filtration rate and risk of terminal renalfailure in proteinuric, non-diabetic nephropathy.Lancet. 1997;(349): 1857-1863

  6. Brenner BM, Cooper ME, de Zeeuw D, KeaneWF, Mitch WE, Parving HH, et al; RENAALStudy Investigators. Effects of losartan on renaland cardiovascular outcomes in patients withtype 2 diabetes and nephropathy. N Engl J Med.2001;345(12):861-9.

  7. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, PohlMA, Lewis JB, et al; Collaborative Study Group.Renoprotective effect of the angiotensin-receptorantagonist irbesartan in patients with nephropathy dueto type 2 diabetes. N Engl J Med. 2001;345(12):851-60.

  8. Campos D, Inserra F, Torrado O, Schiavelli R. Enbusca de la nefroprotección. Rev Nefrol Dial Traspl.2006;26(03):127-133

  9. Zinman B, Wanner C, Lachin JM, Fitchett D,Bluhmki E, Hantel S, et al; EMPA-REG OUTCOMEInvestigators. Empagliflozin, CardiovascularOutcomes, and Mortality in Type 2 Diabetes. N Engl JMed. 2015 Nov 26;373(22):2117-

  10. Wanner Ch, Inzucchi SE, Zinman B. Empagliflozinand Progression of Kidney Disease in Type 2 Diabetes.N Engl J Med. 2016;375(18):1801-1802.

  11. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D,Fulcher G, Erondu N, et al; CANVAS ProgramCollaborative Group. Canagliflozin and Cardiovascularand Renal Events in Type 2 Diabetes. N Engl J Med.2017;377(7):644-657.

  12. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, KatoET, Cahn A; DECLARE–TIMI 58 Investigators.Dapagliflozin and Cardiovascular Outcomes in Type2 Diabetes. N Engl J Med. 2019;380(4):347-357.

  13. Perkovic V, Jardine MJ, Neal B, Bompoint S,Heerspink HJL, Charytan DM, et al; CREDENCETrial Investigators. Canagliflozin and Renal Outcomesin Type 2 Diabetes and Nephropathy. N Engl J Med.2019;380(24):2295-2306.

  14. Heerspink HJL, Stefánsson BV, Correa-Rotter R,Chertow GM, Greene T, Hou FF, et al; DAPA-CKDTrial Committees and Investigators. Dapagliflozin inPatients with Chronic Kidney Disease. N Engl J Med.2020;383(15):1436-1446.

  15. Herrington WG, Staplin N, Wanner C, Green JB,Hauske SJ, Emberson JR, et al, The EMPA-KIDNEYCollaborative Group; Empagliflozin in Patients withChronic Kidney Disease. N Engl J Med. 2023;388:117-127.

  16. McMurray JJ, Solomon SD, Inzucchi SE, Køber L,Kosiborod MN, Martinez FA, et al. Dapagliflozinin Patients with Heart Failure and Reduced EjectionFraction. N Engl J Med. 2019;381:1995-2008.

  17. Packer M, Anker SD, Butler J, et al. Cardiovascularand Renal Outcomes with Empagliflozin in HeartFailure. N Engl J Med. 2020;383:1413-24.

  18. Solomon S, McMurray JV, Claggett B, et alDapagliflozin in heart failure with mildly reducedor preserved ejection fraction. N Engl J Med.2022;387:1089–1098

  19. Anker SD, Butler J, Filippatos G, et al. Empagliflozinin Heart Failure with a Preserved Ejection Fraction. NEngl J Med. 2021;385:1451-1461.

  20. Nuffield Department of Population Health RenalStudies Group, & SGLT2 inhibitor Meta-AnalysisCardio-Renal Trialists’ Consortium (2022). Impactof diabetes on the effects of sodium glucoseco-transporter-2 inhibitors on kidney outcomes:collaborative meta-analysis of large placebo-controlledtrials. Lancet. 2022;400(10365):1788-1801.

  21. Melzer Cohen C, Schechter M, Rozenberg A,et al. Long-Term, Real-World Kidney Outcomeswith SGLT2i versus DPP4i in Type 2 Diabeteswithout Cardiovascular or Kidney Disease. CJASN.2023;18:1153-1162

  22. Inserra F, Castellaro C, Elbert A, Forte E, WaismanG, y cols. Documento de posición sobre el efecto delos iSGLT2 sobre la presión arterial, el daño vascular,la enfermedad renal y el riesgo cardiovascular asociado.Rev Argent Cardiol. 2023;91 (Suplemento 6):1-18.

  23. Inserra F, Castellaro C, Elbert A, Forte E, Waisman G,y cols. Toma de Posición. Efecto de los iSGLT2 sobrela presión arterial, el daño vascular, la enfermedadrenal y el riesgo cardiovascular asociado. Rev NefrolDial Traspl. 2024;44(02):49-51.

  24. Inserra F, Lavenia G, Taylor MF, Castellaro C.Protección cardiovascular, renal y cerebral, de losiSGLT2. Mecanismos hemodinámicos, tisularesy celulares implicados. Rev Nefrol Dial Traspl.2023;43(03):184-196.

  25. Sanz RL, Menéndez SG, Inserra F, Ferder L, ManuchaW. Cellular and Mitochondrial Pathways Contributeto SGLT2 Inhibitors-mediated Tissue Protection:Experimental and Clinical Data. Curr Pharm Des.2024;30(13):969-974.

  26. Williams B, MacDonald TM, Morant S et al.Spironolactone versus placebo, bisoprolol, and doxazosinto determine the optimal treatment for drug resistanthypertension (PATHWAY-2): a randomised, doubleblind,crossover trial. Lancet. 2015;386:2059–2068

  27. Brown NJ. Aldosterone and vascular inflammation.Hypertension. 2008;51:161-167

  28. Yang J, Young MJ. The mineralocorticoid receptorand its coregulators. J Mol Endocrinol. 2009;43:53-64.

  29. Kolkhof P, Jaisser F, Kim SY, Filippatos G,Nowack C, Pitt B. Steroidal and Novel Non-steroidalMineralocorticoid Receptor Antagonists in HeartFailure and Cardiorenal Diseases: Comparison at Benchand Bedside. Handb Exp Pharmacol. 2017;243:271-305.

  30. Bauersachs J, Jaisser F, Toto R. Mineralocorticoidreceptor activation and mineralocorticoid receptorantagonist treatment in cardiac and renal diseases.Hypertension. 2015;65:257-263.

  31. Fujii W, Shibata S. Mineralocorticoid ReceptorAntagonists for Preventing Chronic Kidney DiseaseProgression: Current Evidence and Future Challenges.Int J Mol Sci. 2023; 24:7719

  32. Nishiyama A. Pathophysiological mechanisms ofmineralocorticoid receptor-dependent cardiovascular andchronic kidney disease. Hypertens Res. 2019;42:293-300.

  33. Chrysostomou A, Becker G. Spironolactone inaddition to ACE inhibition to reduce proteinuria inpatients with chronic renal disease. N Engl J Med. 2001Sep 20;345(12):925-6.

  34. ESH/ESC Task Force for the Management ofArterial Hypertension. 2013 Practice guidelines for themanagement of arterial hypertension of the EuropeanSociety of Hypertension (ESH) and the EuropeanSociety of Cardiology (ESC): ESH/ESC Task Forcefor the Management of Arterial Hypertension. JHypertens. 2013;31:1925-1938

  35. Lytvyn Y, Bjornstad P, van Raalte DH, Heerspink HL,Cherney DZI. The New Biology of Diabetic KidneyDisease-Mechanisms and Therapeutic Implications.Endocr Rev. 2020; 41:202–231.

  36. Alicic RZ, Rooney MT, Tuttle KR. Diabetic KidneyDisease: Challenges, Progress, and Possibilities. Clin JAm Soc Nephrol. 2017;12:2032-2045

  37. Barrera-Chimal J, Girerd S, Jaisser F.Mineralocorticoid receptor antagonists and kidneydiseases: pathophysiological basis. Kidney Int. 2019;96:302-319.

  38. Di Lullo L, Lavalle C, Scatena A, Mariani MV, RoncoC, Bellasi A. Finerenone: Questions and Answers-The Four Fundamental Arguments on the New-BornPromising Non-Steroidal Mineralocorticoid ReceptorAntagonist. J Clin Med. 2023;12:3992.

  39. Bakris GL, Agarwal R, Chan JC, Cooper ME,Gansevoort RT, Haller H, et al; MineralocorticoidReceptor Antagonist Tolerability Study–DiabeticNephropathy (ARTS-DN) Study Group. Effect ofFinerenone on Albuminuria in Patients with DiabeticNephropathy: A Randomized Clinical Trial. JAMA.2015;314:884-894.

  40. Agarwal R, Ruilope LM, Ruiz-Hurtado G, Haller H,Schmieder RE, Anker SD, et al. Effect of finerenoneon ambulatory blood pressure in chronic kidneydisease in type 2 diabetes. J Hypertens. 2023;41:295-302.

  41. Bakris GL, Agarwal R, Anker SD, Pitt B, RuilopeLM, Nowack C, et al on behalf of the FIDELIODKDstudy investigators; FIDELIO-DKD studyinvestigators. Design and Baseline Characteristicsof the Finerenone in Reducing Kidney Failure andDisease Progression in Diabetic Kidney Disease Trial.Am J Nephrol. 2019;50:333-344.

  42. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM,Rossing P, et al; FIDELIO-DKD Investigators. Effectof Finerenone on Chronic Kidney Disease Outcomesin Type 2 Diabetes. N Engl J Med. 2020;383:2219-2229.

  43. Ruilope LM, Agarwal R, Anker SD, Bakris GL,Filippatos G, Nowack C, et al; FIGARO-DKD studyinvestigators. Design and Baseline Characteristics ofthe Finerenone in Reducing Cardiovascular Mortalityand Morbidity in Diabetic Kidney Disease Trial. Am JNephrol. 2019;50:345-356.

  44. Pitt B, Filippatos G, Agarwal R, Anker SD, BakrisGL, Rossing P, et al; FIGARO-DKD Investigators.Cardiovascular Events with Finerenone in KidneyDisease and Type 2 Diabetes. N Engl J Med.2021;385:2252-2263.

  45. Yasmin F, Aamir M, Najeeb H, Atif AR, Siddiqui AH,Ahsan MN, et al. Efficacy and safety of finerenone inchronic kidney disease and type 2 diabetes patients:a systematic review and meta-analysis. Ann Med Surg(Lond). 2023;85:4973-4980.

  46. Heerspink HJL, Agarwal R, Bakris GL, Cherney DZI,Lam CSP, Neuen BL et al; FIND-CKD investigators.Design and baseline characteristics of the Finerenone,in addition to standard of care, on the progression ofkidney disease in patients with Non-Diabetic ChronicKidney Disease (FIND-CKD) randomized trial.Nephrol Dial Transplant. 2024 Jun 11:gfae132

  47. Agarwal R, Joseph A, Anker SD, Filippatos G,Rossing P, Ruilope LM, et al; FIDELIO-DKDInvestigators. Hyperkalemia Risk with Finerenone:Results from the FIDELIO-DKD Trial. J Am SocNephrol. 2022; 33:225-237

  48. Zoccali C, Mallamaci F, De Nicola L, Minutolo R.New trials in resistant hypertension: mixed blessingstories. Clin Kidney J. 2023;17(1):sfad251.

  49. Shen L, Kristensen SL, Bengtsson O, Böhm M, deBoer RA, Docherty KF, et al. Dapagliflozin in HFrEFPatients Treated with Mineralocorticoid ReceptorAntagonists: An Analysis of DAPA-HF. JACC HeartFail. 2021;9:254-264.

  50. Heerspink HJL, Vart P, Jongs N, Neuen BL, BakrisG, Claggett B, et al. Estimated lifetime benefit ofnovel pharmacological therapies in patients with type2 diabetes and chronic kidney disease: A joint analysisof randomized controlled clinical trials. Diabetes ObesMetab. 2023;25:3327-3336.

  51. Barrera-Chimal J, Lima-Posada I, Bakris GL, JaisserF. Mineralocorticoid receptor antagonists in diabetickidney disease - mechanistic and therapeutic effects.Nat Rev Nephrol. 2022;18:56-70.

  52. Muskiet MHA, Tonneijck L, Smits MM, et al. GLP-1and the kidney: from physiology to pharmacology andoutcomes in diabetes. Nat Rev Nephrol 2017;13:605-28.

  53. Alshahrani O, Almalki MS. The Efficacy ofPharmacotherapy in the Treatment of Obesity inPatients with Type 2 Diabetes: A Systematic Review.Cureus. 2024 Jul 24;16(7):e65242.

  54. Huang YN, Liao WL, Huang JY, Lin YJ, YangSF, Huang CC, et al. Long-term safety and efficacyof glucagon-like peptide-1 receptor agonists inindividuals with obesity and without type 2 diabetes:A global retrospective cohort study. Diabetes ObesMetab. 2024 Aug 22.

  55. Deanfield J, Verma S, Scirica BM, Kahn SE, EmersonSS, Ryan D, et al; SELECT Trial Investigators.Semaglutide and cardiovascular outcomes inpatients with obesity and prevalent heart failure: aprespecified analysis of the SELECT trial. Lancet.2024;404(10454):773-786.

  56. Elbert A, Castellaro C, Litwak L, Inserra F,Wassermann A, Sinay I. Efectos renales de losagonistas GLP-1 en la diabetes tipo 2. Medicina (BAires). 2022;82:576-590.

  57. Rroji M, Spasovski G. Transforming Diabetes Care:The Molecular Pathways through Which GLP1-RAsImpact the Kidneys in Diabetic Kidney Disease.Biomedicines. 2024;12:657.

  58. Lian K, Zhang K, Kan C, Hou N, Han F, Sun X, QiuH, Guo Z. Emerging therapeutic landscape: Incretinagonists in chronic kidney disease management. LifeSci. 2024;351:122801.

  59. Muskiet MH, Smits MM, Morsink LM, DiamantM. The gut-renal axis: do incretin-based agentsconfer renoprotection in diabetes? Nat Rev Nephrol.2014;10:88-103.

  60. Asmar A, Simonsen L, Asmar M, et al. Renalextraction and acute effects of glucagon-like peptide-1on central and renal hemodynamics in healthy men.Am J Physiol Endocrinol Metab. 2015;308:E641-9.

  61. Giacco F, Du X, Carratu A, et al. GLP-1 cleavage productreverses persistent ROS generation after transienthyperglycemia by disrupting an ROS-generatingfeedback loop. Diabetes 2015;64:3273–84

  62. Wang R, Lu L, Guo Y, Lin F, Chen H, Chen W,Chen M. Effect of Glucagon-like Peptide-1 on High-Glucose-induced Oxidative Stress and Cell Apoptosisin Human Endothelial Cells and Its UnderlyingMechanism. J Cardiovasc Pharmacol. 2015;66:135-140.

  63. Park B, Bakbak E, Teoh H, Krishnaraj A, DennisF, Quan A, et al. GLP-1 receptor agonists andatherosclerosis protection: the vascular endotheliumtakes center stage. Am J Physiol Heart Circ Physiol.2024;326:H1159-H1176.

  64. Marso SP, Daniels GH, Brown-Frandsen K, etal.; LEADER Trial Investigators. Liraglutide andcardiovascular outcomes in type 2 diabetes. N Engl JMed. 2016;375:311-322.

  65. Mann JFE, Fonseca V, Mosenzon O, et al. Effectsof liraglutide versus placebo on cardiovascular eventsin patients with type 2 diabetes mellitus and chronickidney disease. Circulation. 2018;138:2908-2918

  66. Inker LA, Heerspink HJL, Tighiouart H, LeveyAS, Coresh J, Gansevoort RT, et al. GFR Slope as aSurrogate End Point for Kidney Disease Progressionin Clinical Trials: A Meta-Analysis of TreatmentEffects of Randomized Controlled Trials. J Am SocNephrol. 2019;30:1735-1745.

  67. Tuttle KR, Bosch-Traberg H, Cherney DZI, HadjadjS, Lawson J, Mosenzon O, et al. Post hoc analysis ofSUSTAIN 6 and PIONEER 6 trials suggests thatpeople with type 2 diabetes at high cardiovascularrisk treated with semaglutide experience more stablekidney function compared with placebo. Kidney Int.2023;103:772-781.

  68. Sattar N, Lee MMY, Kristensen SL, Branch KRH,Del Prato S, Khurmi NS, et al. Cardiovascular,mortality, and kidney outcomes with GLP-1 receptoragonists in patients with type 2 diabetes: a systematicreview and meta-analysis of randomised trials. LancetDiabetes Endocrinol. 2021;9:653-662.

  69. Tuttle KR, Rayner B, Lakshmanan MC, Kwan AYM,Konig M, Shurzinske L, Botros FT. Clinical Outcomesby Albuminuria Status with Dulaglutide versus InsulinGlargine in Participants with Diabetes and CKD:AWARD-7 Exploratory Analysis. Kidney360. 2020;2:254-262.

  70. Lincoff AM, Brown-Frandsen K, Colhoun HM,Deanfield J, Emerson SS, Esbjerg S, et al; SELECTTrial Investigators. Semaglutide and CardiovascularOutcomes in Obesity without Diabetes. N Engl J Med.2023 Dec 14;389(24):2221-2232.

  71. Colhoun HM, Lingvay I, Brown PM, DeanfieldJ, Brown-Frandsen K, Kahn SE, et al. Long-termkidney outcomes of semaglutide in obesity andcardiovascular disease in the SELECT trial. Nat Med.2024;30:2058-2066

  72. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW,Mann JFE, Bakris G, et al; FLOW Trial Committeesand Investigators. Effects of Semaglutide on ChronicKidney Disease in Patients with Type 2 Diabetes. NEngl J Med. 2024;391:109-121.

  73. Heerspink HJL, Sattar N, Pavo I, Haupt A, DuffinKL, Yang Z, et al. Effects of tirzepatide versus insulinglargine on kidney outcomes in type 2 diabetes in theSURPASS-4 trial: post-hoc analysis of an open-label,randomised, phase 3 trial. Lancet Diabetes Endocrinol.2022;10:774-785.

  74. Neuen BL, Heerspink HJL, Vart P, Claggett BL,Fletcher RA, Arnott C, et al. Estimated LifetimeCardiovascular, Kidney, and Mortality Benefits ofCombination Treatment with SGLT2 Inhibitors,GLP-1 Receptor Agonists, and Nonsteroidal MRACompared with Conventional Care in Patients withType 2 Diabetes and Albuminuria. Circulation. 2024;149:450-462.

  75. Gregg LP, Richardson PA, Nambi V, Petersen LA,Matheny ME, Virani SS, Navaneethan SD. Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation inPatients with CKD. J Am Soc Nephrol. 2024 Aug 26.doi: 10.1681/ASN.0000000000000477.

  76. Herrington WG, Haynes R. Diabetic Kidney Disease- Semaglutide Flows into the Mainstream. N Engl JMed. 2024;391:178-179.

  77. Goldney J, Sargeant JA, Davies MJ. Incretins andmicrovascular complications of diabetes: neuropathy,nephropathy, retinopathy and microangiopathy.Diabetología. 2023; 66:1832-1845.

  78. Kidney Disease: Improving Global Outcomes(KDIGO) CKD Work Group. KDIGO 2024Clinical Practice Guideline for the Evaluation andManagement of Chronic Kidney Disease. Kidney Int.2024;105(4S): S117-S314.




2020     |     www.medigraphic.com